Seek Returns

ALNY vs. JNJ: Alnylam Pharmaceuticals vs. Johnson & Johnson Stock Comparison

How do Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while JNJ is classified in Pharmaceuticals.

Company profile comparison for Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ)
Profile ItemALNYJNJ
NameAlnylam Pharmaceuticals, Inc.Johnson & Johnson
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization20.89 billion USD664.95 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJune 1, 2004January 2, 1962
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ALNY
JNJ
GSPC
Loading price history…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ)
MetricALNYJNJ
Total Return (1Y)-64.57%53.82%
Total Return (3Y, Annualized)-1.58%27.51%
Total Return (5Y, Annualized)-3.13%14.71%

Risk Profile

Drawdown History

ALNY
JNJ
GSPC
Loading price history…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ)
MetricALNYJNJ
Volatility (1Y, Annualized)54.08%21.23%
Beta (5Y)0.450.21
Max Drawdown (5Y)-68.25%-18.41%
Avg. Volume (3M)1.90M6.93M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ALNY and JNJ are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ)
MetricALNYJNJ
Sharpe Ratio (1Y)-1.272.33
Sortino Ratio (1Y)-1.453.66

Profitability

ROE (TTM)

Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Johnson & Johnson (JNJ) at 20.02% also sits in the top quartile.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

138.07%

ALNY
138.07%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max
109.18%
JNJ
20.02%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Alnylam Pharmaceuticals (ALNY) at 52.85% keeps the most of each sales dollar — above its industry’s net margin range — and Johnson & Johnson (JNJ) at 16.20% also retains a top-quartile share.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

52.85%

ALNY
52.85%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.20%

Max
18.05%
JNJ
16.20%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Johnson & Johnson (JNJ) at 25.74% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.72%

Max
83.12%
ALNY
23.72%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.74%

Max
83.12%
JNJ
25.74%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ)
MetricALNYJNJ
ROE (TTM)138.07%20.02%
ROA (TTM)9.51%8.46%
Net Margin (TTM)52.85%16.20%
Operating Margin (TTM)23.72%25.74%
Gross Margin (TTM)77.28%67.78%

Growth

Revenue Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Johnson & Johnson (JNJ) at 6.05% is closer to the peer norm — faster top-line expansion for ALNY.

Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Johnson & Johnson (JNJ) reports EPS growth of 90.50%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.

Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ)
MetricALNYJNJ
Revenue Growth (YoY)65.19%6.05%
Revenue Growth (3Y CAGR)52.98%5.60%
EPS Growth (YoY)--90.50%
EPS Growth (3Y CAGR)--17.90%

Financial Strength

Current Ratio (MRQ)

Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Johnson & Johnson (JNJ) at 1.02 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JNJ.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.48

Max
25.13
Q3
12.13
Median
5.52
ALNY
2.48
Q1
2.47
Min
0.10

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.02

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
JNJ
1.02
Min
0.10
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Johnson & Johnson (JNJ) at 0.55 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max
1.42
ALNY
0.83
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.55

Max
1.42
Q3
0.65
JNJ
0.55
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ)
MetricALNYJNJ
Current Ratio (MRQ)2.481.02
Debt / Equity (MRQ)0.830.55
Net Debt / EBITDA-0.570.79

Dividends

Dividend Yield (TTM)

Alnylam Pharmaceuticals (ALNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

JNJ
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

80.12%

JNJ
80.12%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ)
MetricALNYJNJ
Dividend Yield (TTM)0.00%1.94%
Dividend Payout Ratio (TTM)0.00%80.12%

Valuation

P/E Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Johnson & Johnson (JNJ) at 41.92 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.88

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
ALNY
7.88
Min
0.07

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.92

Max
85.34
Q3
43.46
JNJ
41.92
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Johnson & Johnson (JNJ) at 6.69 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.17

Max
58.18
Q3
25.77
Median
7.30
ALNY
4.17
Q1
3.01
Min
0.01

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max
58.18
Q3
25.77
Median
7.30
JNJ
6.69
Q1
3.01
Min
0.01
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Alnylam Pharmaceuticals (ALNY) at 5.79 is valued about in line with its industry on P/B ratio, while Johnson & Johnson (JNJ) at 8.16 carries an above-peer premium to book — JNJ is pricier on assets.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.79

Max
13.53
Q3
6.54
ALNY
5.79
Median
3.25
Q1
1.69
Min
-5.59

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max
13.53
JNJ
8.16
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Alnylam Pharmaceuticals (ALNY) and Johnson & Johnson (JNJ)
MetricALNYJNJ
P/E Ratio (TTM)7.8841.92
P/S Ratio (TTM)4.176.69
P/B Ratio (MRQ)5.798.16
Free Cash Flow Yield (TTM)1.57%2.78%